<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1831">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05406648</url>
  </required_header>
  <id_info>
    <org_study_id>18-AKD-167</org_study_id>
    <nct_id>NCT05406648</nct_id>
  </id_info>
  <brief_title>The Effect of Black Mulberry (Morus Nigra) Consumption on Cognitive Functions</brief_title>
  <official_title>The Effect of Black Mulberry (Morus Nigra) Consumption on Cognitive Functions and Antioxidant Capacity in Individuals Diagnosed With Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yuksek Ihtisas University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gulhane Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hacettepe University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted with 44 patients who were diagnosed with mild-to-moderate Alzheimer's&#xD;
      Disease. Participants were divided into 2 groups intervention group and the control group.&#xD;
      The intervention group was administered 20 grams of black mulberry concentrate per day for 12&#xD;
      weeks and the control group received no intervention thorough the study. Cognitive functions,&#xD;
      antioxidant capacity, and inflammation markers were evaluated at the baseline and at the end&#xD;
      of the 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the effects of black mulberry on cognitive&#xD;
      functions and biochemical parameters in patients with Alzheimer's disease. The study was&#xD;
      conducted in a tertiary geriatric outpatient clinic with 44 patients aged over 65 years who&#xD;
      were diagnosed with mild-to-moderate AD. The study was completed by 20 participants in the&#xD;
      intervention group and 19 participants in the control group. The intervention group was&#xD;
      administered 20 grams of black mulberry concentrate per day for 12 weeks. There was no&#xD;
      intervention in the control group (n=19). Routine medical treatment for all participants was&#xD;
      continued throughout the study. During the evaluation of the cognitive situation, Mini-Mental&#xD;
      State Assessment (MMSA) and AD Assessment Scale-Cognitive Subscale (ADAS-Cog) test were&#xD;
      administered. Geriatric Depression Scale (GDS-15) was used to screen for depression symptoms.&#xD;
      In order to evaluate antioxidant capacity in serum samples Superoxide dismutase (SOD) enzyme,&#xD;
      Total Oxidant Status (TOS), Total Antioxidant Status (TAS), and oxidative stress index level&#xD;
      were examined. Furthermore, in order to evaluate lipid oxidation, Malondialdehyde (MDA) level&#xD;
      was examined. For the evaluation of inflammation, serum Interleukin 1-beta (IL-1 beta) and&#xD;
      Transforming growth factor-beta (TGF-beta) levels were measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Actual">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognition (ADAS-Cog)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cognition (MMSE)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in Mini-Mental State Examination scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antioxidant capacity (TOS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in serum Total Oxidant Status (TOS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antioxidant capacity (TAS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in serum Total Antioxidant Status (TOS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Alzheimer Disease, Early Onset</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20g of Morus nigra concentrate administration for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention throughout the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Morus nigra concentrate</intervention_name>
    <description>The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To be diagnosed with dementia in the first stage&#xD;
&#xD;
          -  To be using the same medication for dementia throughout the study&#xD;
&#xD;
          -  To have been taking the same dementia medication for the last 6 months and no dose&#xD;
             changes for at least 3 months&#xD;
&#xD;
          -  Not to have used anthocyanin supplement regularly in the last four months before&#xD;
             participating in the study&#xD;
&#xD;
          -  Confirmation of medication use by caregivers&#xD;
&#xD;
          -  To have a caregiver to follow the patient's daily intake of black mulberry concentrate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those under 65 years of age&#xD;
&#xD;
          -  Those who have taken new dementia medication in the last 3 months&#xD;
&#xD;
          -  Those staying in nursing homes&#xD;
&#xD;
          -  Those with mild cognitive impairment who have not yet been diagnosed with dementia&#xD;
&#xD;
          -  Those who have cancer&#xD;
&#xD;
          -  Those with inflammatory diseases (viral or bacterial)&#xD;
&#xD;
          -  History of head trauma that may lead to unconsciousness or other neurological diseases&#xD;
             other than dementia&#xD;
&#xD;
          -  Those with a defined autoimmune disease&#xD;
&#xD;
          -  Alcohol and drug addiction&#xD;
&#xD;
          -  Those with major depression&#xD;
&#xD;
          -  Those with uncontrollable hypertension&#xD;
&#xD;
          -  Those with uncontrolled diabetes&#xD;
&#xD;
          -  Those with dysphagia&#xD;
&#xD;
          -  Tube fed&#xD;
&#xD;
          -  Those who are bedridden&#xD;
&#xD;
          -  Delirium&#xD;
&#xD;
          -  Those who use drugs that may affect outcome measures, such as benzodiazepines&#xD;
&#xD;
          -  Due to the risk that black mulberry may cause possible food-drug interaction via&#xD;
             p-glycoprotein / CYP3A in the literature, patients using the drugs named below will&#xD;
             not be included in the study.&#xD;
&#xD;
               1. Antineoplastic drugs (docetaxel, etoposide, vincristine),&#xD;
&#xD;
               2. Calcium channel blockers (eg amlodipine)&#xD;
&#xD;
               3. Calcineurin inhibitors (tacrolimus and cyclosporine)&#xD;
&#xD;
               4. Digoxin&#xD;
&#xD;
               5. Macrolide antibiotics (Clarithromycin)&#xD;
&#xD;
               6. Protease inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeynep Goktas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>June 1, 2022</study_first_submitted>
  <study_first_submitted_qc>June 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2022</study_first_posted>
  <last_update_submitted>June 3, 2022</last_update_submitted>
  <last_update_submitted_qc>June 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hacettepe University</investigator_affiliation>
    <investigator_full_name>Zeynep Goktas</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

